Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis
Circulatory and Endothelial Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis - Prospective, Observational Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Třebeš
-
Hradec Králové, Třebeš, Czechia, 50005
- University hospital Hradec Králové
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult
- ICU admission due to sepsis with organ failure
- need for organ support therapy (mechanical ventilation, CRRT, ECMO)
- clinical and/or laboratory signs of circulatory instability
Exclusion Criteria:
- family withdrawal/disagreement
- death within three days from ICU admission
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
non-COVID sepsis
Patients admitted to ICU with sepsis of non-COVID origin
|
non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
Other Names:
|
|
COVID sepsis
Patients admitted to ICU with sepsis of COVID origin
|
non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in Proportion of Perfused Vessels (PPV) parameter
Time Frame: 1st, 2nd and 3rd day
|
PPV describes microcirculation dysfunction
|
1st, 2nd and 3rd day
|
|
change in Syndecan-1 serum concentration
Time Frame: 1st, 2nd and 3rd day
|
Syndecan-1 is a marker of endothelial glycocalyx
|
1st, 2nd and 3rd day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in albuminuria
Time Frame: 1st, 2nd and 3rd day
|
albuminuria is a marker of glomerular endothelial cells dysfunction
|
1st, 2nd and 3rd day
|
|
mortality in 28 days
Time Frame: 30 days
|
mortality in 28 days from ICU admission
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia
- Lung Diseases
- Systemic Inflammatory Response Syndrome
- Inflammation
- COVID-19
- Sepsis
- Toxemia
- Pneumonia, Viral
Other Study ID Numbers
Other Study ID Numbers
- FNHK_IGS_8144
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
NCT06809868RecruitingSepsis | Sepsis, Severe | Sepsis and Septic Shock | Sepsis at Intensive Care Unit | Sepsis, Septic Shock | Sepsis, Severe Sepsis and Septic Shock | Sepsis With Multiple Organ Dysfunction (MOD) | Sepsis With Acute Organ Dysfunction
-
NCT07497139Not yet recruitingSepsis Induced Myocardial Dysfunction | Sepsis Induced Cardiomyopathy
-
NCT04979767RecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis Bacteremia
-
NCT05763680RecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal Sepsis
-
NCT03249597CompletedSepsis | Sepsis Syndrome | Sepsis, Severe
-
NCT02232750CompletedSepsis, Severe Sepsis and Septic Shock
-
NCT02135770CompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic Shock
-
NCT03037281CompletedSepsis | Septic Shock | Severe Sepsis | Sepsis Syndrome
-
NCT05304728Enrolling by invitationSevere Sepsis | Severe Sepsis Without Septic Shock
Clinical Trials on microcirculation recording
-
NCT04957303RecruitingSublingual Microcirculation Pattern and Parameter Analysis
-
NCT05096559Recruiting
-
NCT03216850CompletedEndothelial Dysfunction
-
NCT03470792CompletedExtracorporeal Membrane Oxygenation | Microcirculation
-
NCT04169204Active, not recruitingIntensive Care | Microcirculation | Very Old Intensive Care Patients
-
NCT03859726Completed